Antifungal effect of anthraquinones against Cryptococcus neoformans: detection of synergism with amphotericin B

• Published in: Medical mycology (Oxford) 2020-09, Vol.59 (6), p.564-570
• Main Authors: Brilhante, Raimunda Sâmia Nogueira, dos Santos Araújo, Géssica, Fonseca, Xhaulla Maria Quariguasi Cunha, de Melo Guedes, Glaucia Morgana, de Aguiar, Lara, de Souza Collares Maia Castelo-Branco, Débora, de Aguiar Cordeiro, Rossana, Sidrim, José Júlio Costa, Pereira Neto, Waldemiro Aquino, Rocha, Marcos Fábio Gadelha
• Format: Article
• Language: English
• ISSN: 1369-3786; 1460-2709
• DOI: 10.1093/mmy/myaa081

The emergence of tolerant Cryptococcus neoformans strains to antifungals has been described. It has directed researchers to screen for new antimicrobial compounds. In this context, several plant-derived compounds, such as anthraquinones (aloe emodin, barbaloin, and chrysophanol), have been investigated for their antimicrobial properties. This study aimed to evaluate the in vitro effect of aloe emodin, barbaloin and chrysophanol on C. neoformans in vitro growth. In addition, the interaction between these anthraquinones and amphotericin B and itraconazole was evaluated. Initially, the minimum inhibitory concentrations (MIC) of these compounds were determined against 17 strains of C. neoformans by the broth microdilution method and then pharmacological interaction assays were performed with 15 strains by the checkerboard method. Aloe emodin, barbaloin, and chrysophanol showed minimum inhibitory concentrations of 236.82–473.65 μM (64–128 μg/mL), 153–306 μM (64–128 μg/ml) and ≥1007 μM (≥256 μg/ml), respectively. Furthermore, aloe emodin (11/15), barbaloin (13/15), and chrysophanol (12/15) showed pharmacological synergism (FICI